← All trials
NCT05096052
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2021
- Primary completion
- Mar 31, 2022
- Completion date
- May 31, 2022
- First posted
- Oct 27, 2021
- Last posted
- Nov 9, 2021
- Enrollment
- 408
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Bioxytran Inc.Lead sponsor
- Bioxytran Inc.Reponsible party - principal investigator
- ALKE RESEARCH PRIVATE LIMITEDCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.